DCPH:NSD-Deciphera Pharmaceuticals LLC (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 25.5

Change

+0.02 (+0.08)%

Market Cap

USD 2.20B

Volume

1.06M

Analyst Target

USD 73.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-23 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

N/A

USD 13.58B
VTRS Viatris Inc

N/A

USD 12.47B
ITCI Intracellular Th

N/A

USD 7.22B
LNTH Lantheus Holdings Inc

N/A

USD 5.60B
ALKS Alkermes Plc

N/A

USD 4.15B
ALVO Alvotech

N/A

USD 3.93B
HCM HUTCHMED DRC

N/A

USD 3.17B
INDV Indivior PLC Ordinary Shares

N/A

USD 2.47B
AMPH Amphastar P

N/A

USD 1.98B
EVO Evotec SE ADR

N/A

USD 1.74B

ETFs Containing DCPH

QQQS Invesco NASDAQ Future Gen.. 0.82 % 0.00 %

N/A

USD 8.10M
ISMD Inspire Small/Mid Cap Imp.. 0.33 % 0.62 %

N/A

USD 0.19B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

N/A

USD 0.02B
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 58.09% 91% A- 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.09% 91% A- 92% A
Trailing 12 Months  
Capital Gain 82.14% 94% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 82.14% 94% A 93% A
Trailing 5 Years  
Capital Gain 7.73% 79% B- 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.73% 79% B- 52% F
Average Annual (5 Year Horizon)  
Capital Gain -1.69% 51% F 41% F
Dividend Return -1.69% 51% F 36% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 62.22% 39% F 26% F
Risk Adjusted Return -2.72% 50% F 38% F
Market Capitalization 2.20B 90% A- 81% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector